ICU Medical (ICUI) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Viewpoint - ICU Medical reported a revenue of $535.94 million for the quarter ended December 2025, reflecting a 13.8% decline year-over-year, with an EPS of $1.91 compared to $2.11 in the same quarter last year [1] Financial Performance - The reported revenue of $535.94 million exceeded the Zacks Consensus Estimate of $528.97 million, resulting in a surprise of +1.32% [1] - The company achieved an EPS surprise of +13.52%, with the consensus EPS estimate being $1.68 [1] Key Metrics - Revenue from Infusion Systems was $176.3 million, slightly below the average estimate of $177.59 million from two analysts [4] - Revenue from Vital Care reached $79.7 million, surpassing the average estimate of $76.87 million from two analysts [4] - Revenue from Consumables was $284.7 million, exceeding the two-analyst average estimate of $280.64 million [4] Stock Performance - Shares of ICU Medical have returned -2.3% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]